GlassScriptPhysician profile
Gary S Winn
NPI 1922132091
$2,038.36
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $779 · 2021: $45.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $912.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.68 | 2019-2021 | |
| Allergan, INC. | $356.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $170.73 | 2019 | |
| Biodelivery Sciences International, INC. | $123.39 | 2019 | |
| Eisai INC. | $30.92 | 2020 | |
| Merck Sharp & Dohme LLC | $28.01 | 2019 | |
| Novo Nordisk INC | $23.84 | 2020 | |
| Esperion Therapeutics, INC. | $19.41 | 2020 | |
| Pfizer INC. | $14.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Winn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.